SCHEMBL525682

SCHEMBL525682

O=C(O)c1csc(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.76
AMY1A P0DUB6 6/20 0.61
TRPC3 Q13507 1/20 0.58
TRPC6 Q9Y210 1/20 0.58
MEN1 O00255 4/20 0.58
MAPT P10636 4/20 0.58
KMT2A Q03164 4/20 0.58
ALDH1A1 P00352 3/20 0.58
GAA P10253 3/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HPGD P15428 2/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
ALOX5 P09917 3/20 0.54
DEGS1 O15121 1/20 0.54
MAP4K4 O95819 1/20 0.54
CYP3A4 P08684 1/20 0.54
ALOX15 P16050 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28707172 0.88 KDM1A (0.76) KDM1AAMY1ATRPC3TRPC6MEN1
SCHEMBL2285389 0.85 AMY1A (0.60) KDM1AAMY1AMEN1MAPTKMT2A
SCHEMBL525812 0.84 KDM1A (0.56) KDM1AAMY1AMEN1MAPTKMT2A
SCHEMBL4919827 0.84 KDM1A (0.76) KDM1AAMY1AMEN1MAPTKMT2A
SCHEMBL5200233 0.84 MAPT (0.68) KDM1AAMY1ATRPC3TRPC6MEN1
SCHEMBL525319 0.84 KDM1A (0.55) KDM1AAMY1AMEN1MAPTKMT2A
SCHEMBL525271 0.83 KDM1A (0.54) KDM1AAMY1AMEN1MAPTKMT2A
SCHEMBL2870272 0.82 KDM1A (0.78) KDM1AMEN1MAPTKMT2AALDH1A1
SCHEMBL28717687 0.81 KDM1A (0.67) KDM1AAMY1ATRPC3TRPC6MEN1
SCHEMBL525597 0.81 CSNK2A1 (0.65) AMY1ATRPC3TRPC6MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US claimed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
CN-101098698-A 5-carboxamido-substituted thiazole derivatives which interact with ion channels, in particular ion channels of the Kv family DEVGEN NV (BE) 2008-01-02 CN claimed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP claimed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO claimed
EP-3645531-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS Bayer Aktiengesellschaft (DE) 2020-05-06 EP disclosed
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-04-23 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
WO-2019002074-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2019-01-03 WO disclosed
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US disclosed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO disclosed
CN-101098698-A 5-carboxamido-substituted thiazole derivatives which interact with ion channels, in particular ion channels of the Kv family DEVGEN NV (BE) 2008-01-02 CN disclosed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP disclosed
US-20070015665-A1 Thiazoles derivatives as AMPK activator DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
US-20070015665-A1 Thiazoles derivatives as AMPK activator DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
US-20070015665-A1 Thiazoles derivatives as AMPK activator DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
WO-2007005785-A1 THIAZOLES DERIVATIVES AS AMPK ACTIVATOR DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-11 WO disclosed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 KDM1A 162/4885AMY1A 3803/4885TRPC3 4686/4885
US-20070015665-A1 Thiazoles derivatives as AMPK activator PRKAG1, PRKAG2, PRKAB1 KDM1A 4356/4885AMY1A 2240/4885TRPC3 1384/4885
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A KDM1A 18/4885AMY1A 4789/4885TRPC3 1191/4885
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 KDM1A 1458/4885AMY1A 3216/4885TRPC3 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.